You may have heard in the news this weekend that use of the AstraZeneca vaccine has been temporarily suspended. This will affect adults with Down syndrome, who, along with other people in Group 4, may have been offered vaccination soon.
The HSE have sent us some information to share with you (below) which will hopefully answer any questions you may have.
As always, we continue to support people with Down syndrome and their families throughout Ireland – if you require any information or support, please contact us on 01 563 2450 or email us email@example.com.
As you will have heard, a decision has been made to temporarily defer administration of the AstraZeneca COVID-19 vaccine. We are sure that you, your members, your staff and your network would welcome an update on this, and we have prepared the following information for you.
This deferral is being put in place as a precautionary step, while further information about some reported adverse events is reviewed by the EMA, the European Medicines Agency. Our hope is that this precautionary deferral, which will likely be in place for the coming week, will be proven to be just that. As more information is available, we will keep everyone informed.
Questions and Answers
Why has the use of AstraZeneca Vaccine been temporarily deferred?
Following a new safety alert received late on 13th March (from Norway), and pending receipt of further information from the EMA, as a precaution, the National Immunisation Advisory Committee (NIAC) have recommended a temporary deferral of administration of COVID-19 Vaccine AstraZeneca® in Ireland.
Pending further advice, the use of AstraZeneca vaccine will be temporarily deferred for the week commencing the 14th March 2021.
The alert originated from the Norwegian Medicines Agency following four new reports of serious rare clotting, or thromboembolic, events, including some complicated by low platelet levels, or thrombocytopenia, in younger adults. These occurred after vaccination with COVID 19 Vaccine AstraZeneca. At this time, no link between the events and the vaccine have been confirmed.
The EMA is already investigating a number of reports of thromboembolic events from the AstraZeneca Vaccine and a report is expected over the coming days.
EMA information from 12th March was that the number of clotting or thromboembolic events in vaccinated people is no higher than the number seen in the general population. As of 10 March 2021, 30 cases of thromboembolic events had been reported among close to 5 million people vaccinated with COVID-19 Vaccine AstraZeneca® in the European Economic Area.
This vaccine along with the others, is a very important tool in our fight against COVID-19 disease.
Which groups will be affected by this temporary deferral?
Vaccination of people aged 70 and over will not be affected. This group is being vaccinated by their GPs with mRNA vaccines, which are not part of the temporary deferral.
The groups likely to be affected are frontline healthcare workers, and the planned start of vaccinations for Group 4 – people who have conditions that put them at very high risk if they get COVID-19.
What should I do if I have an appointment today or in the next few days to receive COVID-19 Vaccine AstraZeneca® vaccine?
You should not attend your appointment for COVID-19 Vaccine AstraZeneca® until you receive further contact from the HSE or your healthcare team about the resumption of the programme.
You should continue to follow all COVID-19 precautions in the meantime.
Any appointments for a first or second dose of Pfizer or Moderna COVID-19 vaccine can still go ahead as they are not included in this safety alert. This includes appointments for people aged 70 and over who are being vaccinated by GPs.
What about my second dose of COVID-19 Vaccine AstraZeneca® vaccine?
The recommended dose interval between the first and second dose of COVID-19 Vaccine AstraZeneca® is 12 weeks. There are no appointments scheduled for second doses at the present time. Further information will be provided about second doses as soon as it is available
What should I do if I have already received COVID-19 Vaccine AstraZeneca® vaccine?
The events reported are very rare, and we do not know if they are caused by the vaccine. This vaccine is a very important tool in our fight against COVID-19 disease.
We know that side effects of COVID-19 Vaccine AstraZeneca® can occur within the first couple of days of the vaccine.
After the AstraZeneca COVID-19 vaccine, more than 1 in 10 people may experience:
- feeling tired
- tenderness, bruising, pain, redness or itching in the arm where they
- had the vaccine injection
- muscle pain
- joint pain
- nausea, diarrhoea or vomiting
- fever (temperature of 38 degrees Celsius or above)
More than one in 100 people may have redness or swelling where they had the injection.
It’s common to develop a fever (temperature of 38 degrees Celsius or above) after any vaccination. This usually happens within 2 days (48 hours) of getting the vaccine. It usually goes away within 2 days.
If you feel uncomfortable, take paracetamol or ibuprofen following the instructions on the box or leaflet.
What if I still feel unwell more than 3 days after my vaccine?
People who have received the COVID-19 Vaccine AstraZeneca® and feel increasingly unwell for more than three days after vaccination, and/or who notice larger or smaller blue spots in the skin (purpuric, non-blanching rash, skin haemorrhages) should consult a doctor or out-of-hours medical service.
The rare events that have been reported have usually occurred within 14 days of the vaccine. And, it’s important to remember that there is no proven link between these events and the vaccine at this time.
What else should we remember?
COVID-19 is a serious disease which has caused significant disease and death across the world including Ireland. COVID-19 vaccines have been developed and authorised for use after rigorous testing and have a favourable safety profile.
More than 100,000 doses of COVID-19 Vaccine AstraZeneca® have been used in Ireland so far, mainly in frontline healthcare workers, and we can already see the significant reduction in cases of COVID-19 disease in this group after the vaccine programme.
What are the next steps?
Further information is expected from the EMA in the next few days, which will include a review of these additional events. This information will be reviewed by NIAC and further advice on the programme will be issued following this. The HSE, NIAC and the Department of Health will continue to keep people updated and share information as it is available.
This information is also being shared with HSE clinical and service teams nationwide. Our colleagues in the Department of Health and NIAC and our Chief Clinical Officer have all taken part in a range of national media interviews today to share the update and outline the advice to people whose planned appointments may be affected. We are also providing information via our social media channels, and updating the HSE website today. Our team at HSElive are also being given this updated information for anyone who calls us with queries.